Prevention of early recurrence of spontaneous subarachnoid haemorrhage by epsilon-aminocaproic acid
Chowdhary, U.M.; Carey, P.C.; Hussein, M.M.
Lancet 1(8119): 741-743
1979
ISSN/ISBN: 0140-6736 PMID: 85988 Document Number: 150591
A controlled clinical trial of .epsilon.-aminocaproic acid (EACA), 36 g/day, was undertaken to assess its effectiveness in reducing immediate recurrence in patients with spontaneous subarachnoid hemorrhage (SAH) proved by lumbar puncture. Of 83 patients treated with EACA, 3 (4%) had recurrent hemorrhage and 1 (33%) of these died. Of 82 control patients who were not given any antifibrinolytic drug, 22 (26%) had recurrent hemorrhage, and 10 (45%) of these patients died. EACA produced a striking reduction in early recurrence of SAH. No serious side-effects resulted.